Shereef Ahmed Elsammany <br/><br/>
Phase II study of low dose fixed rate infusion of gemcitabine with cisplatin and dexamethazone in resistant non- hodgkin lymphoma and correlation with MDR and BCL -2 expression /  
 دراسة الاستجابة للتنقيط الوريدى ذو المعدل الثابت لعقار الجمستابين مع السيزبلاتين و الديكساميثازون فى حالات الليمفوما من نوع غير الهودحكين غير المستجيبة للعلاج الكيميائى و علاقة وجود جين م.د.ر و جين ب س ل2 بالاستجابة لهذا البرنامج العلاجى 
Shereef Ahmed Elsammany ; Supervised Mostafa Mahmoud Elserafy , Sameh Sayed Ahmed Shamaa , Mona Ali Sakr 
 - Cairo :   Shereef Ahmed Elsammany ,   2010 
 - 202P. :   charts ;   25cm 
<br/><br/>Thesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Oncology-Medical 
<br/><br/> Despite significant advances in the managment of patients with aggressive non - hodgkin's lymphomas (NHLs) significant proportion of patients still experience relapse following initial response to therapy or even not responding to chemotherapy from the start . So there is a great priority for the development of new chemotherapy regimens in addition to new prognostic factors for respone and survival in patients with resistant disease 
<br/><br/>
<br/><br/><label>Subjects--Index Terms: </label>Fixed rate  Gemcitabine  N.H.L